In this study, the investigators will recruit a cohort of elderly Black and Hispanic patients with heart failure to define the number of patients who have cardiac amyloidosis by utilizing highly sensitive heart imaging and blood tests. The investigators will also explore differences in genetics and sex as they relate to heart failure disease progression in cardiac amyloidosis.

Start Date15 May 2019

Sponsor / Collaborator

Columbia University

[+5]

100 Clinical Results associated with Technetium(99mTc) Hydroxymethylenediphosphonate

100 Translational Medicine associated with Technetium(99mTc) Hydroxymethylenediphosphonate

100 Patents (Medical) associated with Technetium(99mTc) Hydroxymethylenediphosphonate

Literatures (Medical) associated with Technetium(99mTc) Hydroxymethylenediphosphonate

01 Jun 2024·Radiological Physics and Technology

Feasibility study of radioactivity estimation of 99mTc and 123I-labeled radiopharmaceuticals using shielded syringes

Article

Author: Yasuno, Narumi ; Nakamura, Yuto

This study investigates the feasibility of estimating the radioactivity of radiopharmaceuticals using shielded syringes. The radioactivities of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were measured using a dose calibrator. Correlation coefficients and regression equations were obtained from the radioactivity in the shielded and unshielded syringes. ^99mTc-MDP was also measured for residual radioactivity after the administration. The correlation coefficients of ^99mTc-MDP, ^99mTc-HMDP, ^99mTc-ECD, ^99mTc-MAG₃, and ¹²³I-IMP were r_s = 0.9998, r_s = 0.9997, r_s = 0.9999, r_s = 0.9998, and r_s = 0.9888, respectively. The regression equations were y = 0.0364x + 0.0913, y = 0.0349x + 0.0273, y = 0.0343x - 0.0018, y = 0.0522x + 0.1215, and y = 0.0383x + 0.0058, respectively. The correlation coefficient for the residual radioactivity of ^99mTc-MDP was r_s = 0.9887 and the regression equation was y = 0.1505x + 0.0853. The radioactivity of ^99mTc- and ¹²³I-labeled radiopharmaceuticals in shielded syringes was accurately measured. It was suggested that the measuring shielded syringes could provide an estimate of the actual radioactivity.

01 Jan 2024·Japanese Journal of Radiological Technology

Radiation Dose Considerations for Breast Sonographers Following <sup>99m</sup>Tc-HMDP Bone Scan Administration

Article

Author: Tsukada, Ryota ; Wagatsuma, Kei ; Suzuki, Hiroaki

PURPOSEPatients who were administered radiopharmaceuticals can be a source of radiation exposure to sonographers. This study aimed to identify factors associated with radiation exposure to breast sonographers from patients administered radiopharmaceuticals for bone scanning.METHODSThe exposure dose of six sonographers was measured during breast sonography in 59 patients administered ^99mTc-HMDP. We predicted the following factors to be related to exposure dose: time interval between administration and sonography, sonography examination time, estimated radioactivity at sonography, sonographer's years of experience, and patients' clinical data (age, renal function and surgical procedure). Spearman's rank correlation coefficient was used to examine the relationship between radiation dose and the aforementioned factors.RESULTSThe mean±standard deviation of the exposure dose for the sonographers was 9.3±3.8 µSv. The time interval between administering the radiopharmaceutical agent and sonography, the sonography examination time and estimated radioactivity at sonography were found to be factors related to the exposure of the sonographer. The exposure dose increased as a function of the shorter time interval, longer examination time and higher estimated radioactivity at sonography.CONCLUSIONThe time interval between drug administration and sonography, sonography examination time and estimated radioactivity at sonography contributed to the increased dose to breast sonographers. Although we considered that the exposure dose of sonographers would not possibly exceed the dose limit in the present study, we suggested that radiological technologists need to educate the physicians requesting sonography, and the sonographers about the radiation exposure in nuclear medicine.

01 Oct 2022·InjuryQ3 · MEDICINE

99mTc-polyphosphonate labelling – Enhancement of a novel method for the quantification of osteogenic differentiation of MSCs in vitro

Q3 · MEDICINE

Article

Author: Schmidmaier, Gerhard ; Gotterbarm, Tobias ; Haberkorn, Uwe ; Grossner, Tobias ; Helbig, Lars

Bone tissue engineering is a fast-growing field in regenerative medicine. Consequently, there is a high demand for new, fast and reliable methods to track and quantify the osteogenic differentiation of cells. Recently, a novel method was published to non-destructively quantify the hydroxyapatite content of monolayer and 3-dimensional mesenchymal stem cell cultures using the ability of ⁹⁹^mTechnetium-methylene diphosphonate (MDP), a well-established tracer in clinical nuclear medicine, to bind to newly synthesized hydroxyapatite. In the present study, two other commonly used ⁹⁹^mTechnetium tracers, 2,3-dicarboxypropane-1,1-diphosphonate (DPD) and hydroxydiphosphonate (HDP), were evaluated to see if they could also be used for the same purpose. Furthermore, we investigated if labelling at various timepoints influenced the effectiveness of the labelling. The results were analysed using one-factor ANOVA followed by Bonferroni post-hoc testing. This revealed a highly significant difference between the three osteogenic groups at each timepoint compared to their corresponding negative controls. However, there was no statistically significant difference between the three different tracers (MDP, DPD, HDP) in the osteogenic groups. Therefore all three tracers are of similar value when quantifying the extracellular hydroxylapatite content in osteogenic stem cells cultures.

100 Deals associated with Technetium(99mTc) Hydroxymethylenediphosphonate

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diagnostic agents	JP	Nihon Medi-Physics Co., Ltd.	15 Dec 1982

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 1	-	University of Cincinnati Physicians Co. LLC	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2023	Not Applicable	-	-	Osteogenic supplements (dexamethasone, L-ascorbic acid, and β-glycerol phosphate)	sdiadrdsvh(uglchqqpjl) = revealed no statistically significant difference at timepoint d21 between group 1 (219,103 cells counted) and group 7 (231,694 cells counted) bvrcehfphc (kcxhqtxokt )	-	28 Aug 2023
				99mTc-HDP (Non-osteogenic controls)
SNMMI2022	Not Applicable	-	-	99mTc-HDP (Osteogenic group OM)	fnwrfxgjrk(zlcxhowwpr) = runicpgzoc ajrzmcdpcq (pmryxroijt )	-	08 Aug 2022
				99mTc-HDP (Control group CTRL)	fnwrfxgjrk(zlcxhowwpr) = exrgaryxdp ajrzmcdpcq (pmryxroijt )
SNMMI2019	Not Applicable	Transthyretin cardiac amyloidosis	7	99m Tc-HMDP (Patients with cardiac ATTR)	huoxusxgyq(jvxfiqehtd) = ctfotwhdxw benjjkpvee (gekhdpmzlx )	Positive	21 May 2019
				99m Tc-HMDP (Control group)	huoxusxgyq(jvxfiqehtd) = lhdpnpmpla benjjkpvee (gekhdpmzlx )
SNMMI2016	Not Applicable	-	-	99mTc-HDP (DMEM low glucose)	uqddysxeqg(liopeqljdp) = xlnzzugqrq pgflprfxqq (srrhvgcgnf )	-	24 May 2016
				99mTc-HDP (DMEM high glucose)	uqddysxeqg(liopeqljdp) = otjjpsgpnz pgflprfxqq (srrhvgcgnf )
SNMMI2016	Not Applicable	Transthyretin cardiac amyloidosis	-	99mTc-HMDP (wt-TTR-CA)	edaxrbqtxy(ikbjxoxsib) = vpmybyhipa pewmxzhukv (jyxvstjivp, 11.8)	-	24 May 2016
				99mTc-HMDP (m-TTR-CA)	edaxrbqtxy(ikbjxoxsib) = keyeqwijhd pewmxzhukv (jyxvstjivp, 9.3)
SNMMI2015	Not Applicable	Amyloidosis, Hereditary, Transthyretin-Related	55	99m Tc HMDP (Transthyretin-type (TTR) amyloidosis)	cnfwhvuoao(betvarrwls) = hqkwnnlhmn olguopirbr (bzwqquxgtq )	Positive	15 May 2015
				99m Tc HMDP (Wild-type transthyretin cardiac amyloidosis (wt-TTR-CA))	cnfwhvuoao(betvarrwls) = dwrkqypapz olguopirbr (bzwqquxgtq )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Technetium(99mTc) Hydroxymethylenediphosphonate

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation